GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » ROIC %

Lifecore Biomedical (Lifecore Biomedical) ROIC % : -3.88% (As of May. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Lifecore Biomedical's annualized return on invested capital (ROIC %) for the quarter that ended in May. 2023 was -3.88%.

As of today (2024-05-22), Lifecore Biomedical's WACC % is 10.84%. Lifecore Biomedical's ROIC % is -8.30% (calculated using TTM income statement data). Lifecore Biomedical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Lifecore Biomedical ROIC % Historical Data

The historical data trend for Lifecore Biomedical's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical ROIC % Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 -1.34 0.74 -0.65 -7.81

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.49 -9.17 -8.17 -10.84 -3.88

Competitive Comparison of Lifecore Biomedical's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's ROIC % distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's ROIC % falls into.



Lifecore Biomedical ROIC % Calculation

Lifecore Biomedical's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in May. 2023 is calculated as:

ROIC % (A: May. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: May. 2022 ) + Invested Capital (A: May. 2023 ))/ count )
=-19.72 * ( 1 - -0.48% )/( (306.244 + 201.07)/ 2 )
=-19.814656/253.657
=-7.81 %

where

Lifecore Biomedical's annualized Return on Invested Capital (ROIC %) for the quarter that ended in May. 2023 is calculated as:

ROIC % (Q: May. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Feb. 2023 ) + Invested Capital (Q: May. 2023 ))/ count )
=-7.844 * ( 1 - -0.79% )/( (206.429 + 201.07)/ 2 )
=-7.9059676/203.7495
=-3.88 %

where

Note: The Operating Income data used here is four times the quarterly (May. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifecore Biomedical  (NAS:LFCR) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Lifecore Biomedical's WACC % is 10.84%. Lifecore Biomedical's ROIC % is -8.30% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Lifecore Biomedical ROIC % Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318